Business Wire
December 8, 2010
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and
Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo’s proprietary platform for the creation of 3D tissue constructs.
Dr. Craig Kent, Chief of Surgery at the University of Wisconsin and an Organovo Scientific Advisory Board Member commented, “This is exciting progress towards functional human arterial grafts. Success in an effort like this could eventually help tens of thousands of patients.”
